HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) materials and methods Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Hamidi, S. A. Articles by Said, S. I. Search for Related Content PubMed PubMed Citation Articles by Hamidi, S. A. Articles by Said, S. I.

Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion

¹ Pulmonary and Critical Care Medicine, State University of New York, Stony Brook, ² Dept of Veterans Affairs Medical Center, Northport, NY, and ³ SuperArray Bioscience Corporation, Fredrick, MD, USA.

CORRESPONDENCE: S. I. Said, Pulmonary and Critical Care Medicine, State University of New York Health Sciences Center, T-17-040, Stony Brook, NY 11784-8172, USA. Fax: 1 6314447502. E-mail: sami.i.said{at}stonybrook.edu

Keywords: Gene expression and regulation, pulmonary hypertension, quantitative PCR, right heart failure

Received: August 13, 2007
Accepted September 27, 2007

The pathogenesis of idiopathic pulmonary arterial hypertension (PAH) remains poorly understood. The present authors recently reported that mice with vasoactive intestinal peptide (VIP) gene disruption show a spontaneous phenotype of PAH, with pulmonary vascular remodelling and lung inflammation.

To explore the underlying molecular mechanisms in this model, it was examined whether absence of the VIP gene might alter the expression of additional genes involved in the pathogenesis of PAH, as single-gene deletions, in the absence of hypoxia, rarely result in significant pulmonary vascular remodelling.

Lung tissue from mice with targeted disruption of the vasoactive intestinal peptide gene (VIP^-/- mice) and from control mice was subjected to whole-genome gene microarray analysis, and the results validated with quantitative, real-time PCR. Lungs from VIP^-/- mice showed a wide range of significant gene expression alterations, including overexpression of genes that promote pulmonary vascular smooth muscle cell proliferation, underexpression of antiproliferative genes and upregulation of pro-inflammatory genes.

In conclusion, vasoactive intestinal peptide is a pivotal modulator of genes controlling the pulmonary vasculature, its deficiency alone resulting in gene expression alterations that can readily explain both the vascular remodelling and associated inflammatory response in pulmonary arterial hypertension. The present findings shed more light on the molecular mechanisms of pulmonary arterial hypertension, and could lead to better understanding of the pathogenesis of human pulmonary arterial hypertension, and hence to improved therapy.

This article has been cited by other articles:

				S. I. Said Animal models of airway hyperresponsiveness Eur. Respir. J., January 1, 2009; 33(1): 217 - 218. [Full Text] [PDF]

				M. Humbert Update in Pulmonary Arterial Hypertension 2007 Am. J. Respir. Crit. Care Med., March 15, 2008; 177(6): 574 - 579. [Full Text] [PDF]